Table 1 Baseline characteristics of study participants according to known age-of-onset of diabetes.
From: Rate of decline in kidney function and known age-of-onset or duration of type 2 diabetes
Characteristics | Overall | Known age-of-onset of diabetes (years) | ||||
|---|---|---|---|---|---|---|
0–39 | 40–49 | 50–59 | 60–69 | 70+ | ||
n (%) | 9917 | 945 (9.5) | 2926 (29.5) | 4264 (43) | 1561 (15.8) | 221 (2.2) |
Baseline age (yr; median [IQR]) | 62.0 (57.6, 67.0) | 58.0 (55.3, 62.6) | 58.8 (56.1, 62.8) | 61.8 (58.4, 65.7) | 69.1 (66.1, 72.4) | 76.2 (74.1, 78.1) |
Diabetes duration (yr; median [IQR]) | 9.0 (5.0, 15.0) | 23.0 (19.0, 30.0) | 13.0 (10.0, 18.0) | 7.0 (4.0, 11.0) | 5.0 (3.0, 8.0) | 3.0 (1.0, 5.0) |
Follow-up (yr, mean [SD]) | 7.0 (2.7) | 6.9 (3.1) | 7.0 (3.1) | 7.1 (3.1) | 6.6 (3.0) | 5.5 (2.7) |
Male (n [%]) | 6107 (61.6) | 542 (57.3) | 1815 (62.0) | 2633 (61.7) | 983 (63.0) | 136 (61.5) |
Race (n [%]) | ||||||
White | 6191 (62.4) | 504 (53.3) | 1736 (59.3) | 2714 (63.7) | 1083 (69.4) | 154 (69.7) |
Black | 1883 (19.0) | 217 (23.0) | 595 (20.3) | 773 (18.1) | 261 (16.7) | 37 (16.7) |
Hispanic | 709 (7.2) | 97 (10.3) | 216 (7.4) | 311 (7.3) | 72 (4.6) | 13 (5.9) |
Other | 1134 (11.4) | 127 (13.4) | 379 (13.0) | 466 (10.9) | 145 (9.3) | 17 (7.7) |
Education (n [%]) | ||||||
< High school | 1442 (14.5) | 147 (15.5) | 391 (13.4) | 588 (13.8) | 270 (17.3) | 46 (20.8) |
High school graduate | 2620 (26.4) | 266 (28.2) | 722 (24.7) | 1102 (25.8) | 466 (29.8) | 64 (28.9) |
Some college | 3257 (32.9) | 312 (33.1) | 1016 (34.7) | 1406 (33.0) | 463 (29.7) | 60 (27.2) |
≥ College graduate | 2598 (26.2) | 220 (23.2) | 797 (27.2) | 1167 (27.4) | 362 (23.2) | 51 (23.1) |
Current smoker (n [%]) | 1375 (13.9) | 145 (15.3) | 451 (15.4) | 594 (13.9) | 169 (10.8) | 16 (7.2) |
HbA1c (%; median [IQR]) | 8.1 (7.6, 8.9) | 8.3 (7.8, 9.1) | 8.2 (7.7, 9.0) | 8.1 (7.5, 8.8) | 7.9 (7.5, 8.6) | 7.8 (7.3, 8.6) |
HbA1c (mmol/mol; median [IQR]) | 65.0 (58.5, 72.3) | 67.2 (61.7, 75.9) | 66.1 (60.6, 74.9) | 65.0 (58.5, 72.7) | 62.8 (58.5, 70.5) | 61.7 (56.3, 70.5) |
Insulin use (n [%]) | 3480 (35.1) | 637 (67.4) | 1360 (46.5) | 1161 (27.2) | 298 (19.1) | 24 (10.8) |
BMI (kg/m2; mean [SD]) | 32.2 (5.4) | 32.2 (5.6) | 32.5 (5.5) | 32.4 (5.3) | 31.4 (4.9) | 30.2 (4.8) |
Triglycerides (mg/dL; median [IQR]) | 155 (106, 228) | 137 (94.5, 202) | 151 (102, 232) | 160 (112, 236) | 157 (109.5, 218.5) | 148 (99, 218) |
Total cholesterol (mg/dL; median [IQR]) | 178 (154, 207) | 174 (149, 201) | 177 (153, 208) | 181 (157, 209) | 176 (153, 203) | 171 (147, 198) |
Systolic BP (mmHg; mean [SD]) | 136.3 (17.0) | 136.2 (17.1) | 136.1 (16.9) | 135.8 (16.8) | 137.5 (18.0) | 139.0 (16.5) |
RAAS blockers (n [%]) | 6858 (69.1) | 698 (73.8) | 2102 (71.8) | 2864 (67.2) | 1039 (66.5) | 154 (70.1) |
CVD history (n [%]) | 3472 (35.0) | 474 (50.1) | 1113 (38.0) | 1241 (29.1) | 554 (35.5) | 90 (40.9) |
UACR (mg/g; median [IQR]) | 14 (7, 44) | 20 (8, 86.5) | 14 (7, 50) | 13 (7, 37) | 12 (7, 37) | 17 (7, 43) |
UACR categories | ||||||
A1 (normoalbuminuria) | 6801 (68.6) | 538 (56.9) | 1949 (66.6) | 3062 (71.8) | 1108 (71.0) | 144 (65.2) |
A2 (microalbuminuria) | 2468 (24.9) | 297 (31.4) | 743 (25.4) | 991 (23.2) | 371 (23.8) | 66 (29.9) |
A3 (macroalbuminuria) | 648 (6.5) | 110 (11.7) | 234 (8.0) | 211 (5.0) | 82 (5.2) | 11 (4.9) |
eGFR (mL/min/1.73 m2; median [IQR]) | 87.2 (72.2, 96.7) | 91.2 (72.7, 99.4) | 91.3 (75.6, 99.1) | 88.8 (73.1, 96.8) | 78.6 (66.7, 90.4) | 71.5 (58.6, 83.0) |
eGFR categories (mL/min/1.73 m2) | ||||||
G1 (> 90) | 4515 (45.5) | 491 (52.0) | 1549 (52.9) | 2034 (47.7) | 422 (27.1) | 19 (8.6) |
G2 (60–90) | 4414 (44.5) | 362 (38.3) | 1149 (39.3) | 1838 (43.1) | 923 (59.1) | 142 (64.3) |
G3 (< 60) | 988 (10.0) | 92 (9.7) | 228 (7.8) | 392 (9.2) | 216 (13.8) | 60 (27.1) |
